Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.69 |
| ▸ | HCAR3 | P49019 | 7/20 | 0.63 |
| ▸ | HPGD | P15428 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.59 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.59 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.56 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.56 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.56 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14402 | 0.91 | AKR1C3 (0.57) | MAPTHCAR3HPGDKMT2AMEN1 | |
| SCHEMBL12004226 | 0.91 | MAPT (0.56) | MAPTHCAR3KMT2AMEN1LMNA | |
| SCHEMBL9725390 | 0.89 | MAPT (0.56) | MAPTHCAR3HPGDKMT2AMEN1 | |
| SCHEMBL12061579 | 0.88 | MAPT (0.54) | MAPTHCAR3HPGDKMT2AMEN1 | |
| SCHEMBL6044113 | 0.88 | MAPT (0.77) | MAPTHCAR3HPGDKMT2AMEN1 | |
| SCHEMBL6044783 | 0.87 | MAPT (0.67) | MAPTHCAR3HPGDKMT2AMEN1 | |
| SCHEMBL992446 | 0.85 | HCAR3 (0.68) | MAPTHCAR3KMT2AMEN1LMNA | |
| SCHEMBL5476932 | 0.84 | FFAR1 (0.59) | MAPTHPGDKMT2AMEN1LMNA | |
| SCHEMBL9683146 | 0.81 | MAPT (0.57) | MAPTHPGDKMT2AMEN1LMNA | |
| SCHEMBL28808881 | 0.81 | MAPT (0.57) | MAPTHPGDKMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122240-A1 | Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
| WO-2004041274-A1 | BENZOTRIAZOLES AND METHODS OF PROPHYLAXIS OR TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122240-A1 | Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof | GCGR, GPR119, HMGCR | MAPT 3284/4885HCAR3 85/4885HPGD 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.